Hyderabad

VBPL is an ISO 13485:2012 and WHO – GMP certified leading global player in Biopharma sector having more than 15 years of operational experience, situated at Hyderabad. We also have offices located in USA. Innovative, ever motivated Research team and uncompromising manufacturing team in providing quality products are our strengths.

Requirement of Manpower for QA (IPQA & QMS)

VBPL is an ISO 13485:2012 and WHO – GMP certified leading global player in Biopharma sector having more than 15 years of operational experience, situated at Hyderabad. We also have offices located in USA. Innovative, ever motivated Research team and uncompromising manufacturing team in providing quality products are our strengths.

Requirement of Manpower for Manufacturing (Vial, Cartridge, PFS & BFS)

The National Institute of Nutrition is an Indian public health, nutrition and translational research centre located in Hyderabad, India. The institute is one of the oldest research centres in India, and the largest centre, under the Indian Council of Medical Research, located in the vicinity of Osmania University.

Hetero Drugs is an Indian pharmaceutical company and the world’s largest producer of anti-retroviral drugs. Hetero’s business includes APIs, generics, biosimilars, custom pharmaceutical services, and branded generics. Globally renowned, vertically integrated pharmaceutical player engaged in Research and Development (R&D), manufacturing, and marketing of high-quality chemical and biologic medicines across diverse therapeutic areas.

Openings for Regulatory Affairs

Established in 2012, Honour Lab Limited is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs) & Intermediates. Honour Lab Limited has 5 state-of-the-art manufacturing facilities located in Hyderabad, Visakhapatnam and Pune which are approved by USFDA, TGA, MFDS, MOT, PMDA and PICS. Backed by a strong R&D with 100+ top notch scientists, the company excels at developing high-quality products which meet the demands of the rapidly growing global drug markets.